NTRK2 and metastatic neoplasm: STS patients had a 5-year OS rate of 78% in 2013–2019.43 However, the 2-, and 5-year OS rates of STS with metastatic disease were 49.9% and 24.8%, respectively.18,44 Median OS were between 12 and 24 months.44, –46 STS patients treated in the clinical trial UNRESARC (NCT03651375) conducted in our department were estimated to have 2- and 3-year OS rates of 67% and 53%, respectively.31 However, both patients with detected PRUNE2::NTRK2 gene fusion are currently alive, more than 7 years after starting treatment at our sarcoma center.